ViaCyte, a company that CIRM has supported for many years, has announced international expansion of a clinical trial to test their therapeutic PEC-Direct product in patients with Type I Diabetes. The first European patient in Brussels was implanted with the PEC-Direct product candidate that, in animal models, is able to form functional beta cells. Patients … Continue reading CIRM-supported Type I Diabetes treatment enters clinical trials in Europe
ViaCyte
How CIRM support helped a promising approach to type 1 diabetes get vital financial backing
The “Valley of Death” sounds like a scary place from “Lord of the Rings” or “Game of Thrones” that our heroes have to navigate to reach safety. The reality is not that different. It’s the space that young companies have to navigate from having a good idea to getting financial backing, so they can move … Continue reading How CIRM support helped a promising approach to type 1 diabetes get vital financial backing
New partnership to make CIRM supported treatment for type 1 diabetes even better
ViaCyte, a regenerative medicine company long backed by CIRM, announced a partnership with CRISPR Therapeutics to increase the number of people with Type 1 Diabetes (T1D) who could benefit from their PEC-Direct therapeutic implant. Last year, CIRM granted ViaCyte $20 million to facilitate development of PEC-Direct, a device that both transplants pancreatic progenitor stem … Continue reading New partnership to make CIRM supported treatment for type 1 diabetes even better
CIRM-Funded Research Makes Multiple Headlines this Week
When it rains it pours. This week, multiple CIRM-funded studies appeared in the news, highlighting the exciting progress our Agency is making towards funding innovative stem cell research and promoting the development of promising stem cell therapies for patients. Below are highlights. Fate Therapeutics Partners with UC San Diego to Develop Cancer Immunotherapy Last week, … Continue reading CIRM-Funded Research Makes Multiple Headlines this Week
Stem Cell Stories that Caught Our Eye: New law to protect consumers; using skin to monitor blood sugar; and a win for the good guys
New law targets stem cell clinics that offer therapies not approved by the FDA For some time now CIRM and others around California have been warning consumers about the risks involved in going to clinics that offer stem cell therapies that have not been tested in a clinical trial or approved by the U.S. Food … Continue reading Stem Cell Stories that Caught Our Eye: New law to protect consumers; using skin to monitor blood sugar; and a win for the good guys
CIRM-Funded Clinical Trials Targeting the Heart, Pancreas, and Kidneys
This blog is part of our Month of CIRM series, which features our Agency’s progress towards achieving our mission to accelerate stem cell treatments to patients with unmet medical needs. This week, we’re highlighting CIRM-funded clinical trials to address the growing interest in our rapidly expanding clinical portfolio. Today we are featuring trials in our … Continue reading CIRM-Funded Clinical Trials Targeting the Heart, Pancreas, and Kidneys
CIRM Board Appoints Dr. Maria Millan as President and CEO
Yesterday was a big day for CIRM. Our governing Board convened for its September ICOC meeting and appointed Dr. Maria Millan as our new President and CEO. Dr. Millan has been serving as the Interim President/CEO since July, replacing former President Dr. Randal Mills. Dr. Millan has been at CIRM since 2012 and was instrumental … Continue reading CIRM Board Appoints Dr. Maria Millan as President and CEO
ViaCyte treats first patients in PEC-Direct stem cell trial for type 1 diabetes
Today, ViaCyte shared an update on its latest clinical trial for type 1 diabetes (T1D). The company is based in San Diego and is developing two stem cell-based products that attempt to replace the pancreatic beta islet cells that are attacked by the immune system of patients with T1D. Their first product, called VC-01 or … Continue reading ViaCyte treats first patients in PEC-Direct stem cell trial for type 1 diabetes
Wall Street Journal features CIRM-funded clinical trials aiming for a diabetes cure
We think CIRM-funded clinical trials hold so much promise that it doesn’t surprise us when major news organizations publish stories about these projects that aim to provide stem cell treatments to patients with unmet medical needs. But we certainly don’t mind the attention! This past Saturday, for example, the Wall Street Journal featured two CIRM-funded … Continue reading Wall Street Journal features CIRM-funded clinical trials aiming for a diabetes cure
ViaCyte Advances Cell Replacement Therapy for High Risk Type 1 Diabetes
San Diego regenerative medicine company ViaCyte announced this week that the Food and Drug Administration (FDA) approved their Investigational New Drug (IND) Application for PEC-Direct, a cell-based therapy to treat patients at risk for severe complications caused by type 1 diabetes. In the US, IND approval is the final regulatory step required before a therapy … Continue reading ViaCyte Advances Cell Replacement Therapy for High Risk Type 1 Diabetes